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PNM15
DO PEOPLE CONSIDER THE EFFECTS OF 
ILL-HEALTH ON INCOME AND LEISURE WHEN
ANSWERING HEALTH-RELATED QUALITY-
OF-LIFE QUESTIONS?
Sendi P1, Brouwer WBF2
1Basel University Hospital, Basel, Switzerland; 2Erasmus
University Rotterdam, Rotterdam, Netherlands
OBJECTIVES: The objective of the present study was to
evaluate whether people do include the effects of ill-health
on income and leisure in quality of life valuation when
the measure is silent on both. METHODS: A convenience
sample of 20 health professionals (5 medical doctors, 2
medical researchers, and 13 nurses) were administered a
questionnaire that described the health status of a 30-year
old male patient suffering from multiple sclerosis (MS).
Respondents rated that health status on a visual analogue
scale (VAS) and were thereafter asked whether the impact
of ill-health on income and leisure was included in their
valuation. In case either answer was negative, they were
explicitly asked to consider these effects in a second VAS
question. RESULTS: Twelve (60%) respondents did not
consider the effects of ill-health on income whereas only
5 (25%) respondents did not consider the effects of ill-
health on leisure. The mean VAS score was signiﬁcantly
higher among respondents who did not consider income
(48.33 versus 31.25, p = 0.036). Among those who did
not considered leisure or income in the ﬁrst VAS ques-
tion, the mean VAS of the second question was signiﬁ-
cantly lower (mean difference 7.89, p = 0.005). However,
5 respondents (25%) who did not consider income in the
ﬁrst VAS question did not change their VAS score in 
the second question. CONCLUSIONS: The majority of
respondents did not consider the effects of ill-health on
income but on leisure. Moreover, respondents may not
include the effects of ill-health on income even when they
are explicitly asked to do so. Our results are in line with
the argument that productivity costs related to paid work
should be included as costs whereas productivity costs
related to leisure time should be captured in the QALY.
Still, health state valuations may need to be more explicit
in this respect.
PNM16
THE COSTS OF MULTIPLE SCLEROSIS—A
CROSS-SECTIONAL PROSPECTIVE MULTI-
CENTRE COST OF ILLNESS STUDY IN POLAND
Orlewska E1, Mierzejewski P1, Zaborski J2, Czlonkowska A2
1Medical University of Warsaw, Warsaw, Poland; 2Institute of
Psychiatry and Neurology, Warsaw, Poland
OBJECTIVE: To estimate the costs of multiple sclerosis
(MS) in Poland according to severity of disease.
METHODS: Enrolled were 148 outpatients with MS at
3 centres across Poland. Socio-demographic, clinical and
resource utilization data were collected using a validated
questionnaire over a 5-month period. Total, direct and
indirect costs were compared among three groups cate-
gorised by disease severity (EDSS score): stages I, II and
III, corresponding to mild (EDSS 1–3, 5, n = 57), moder-
ate (EDSS 4–6, n = 56) and severe (EDSS 6, 5–8, n = 35)
MS, respectively. Cost evaluation was performed from
both the public payer and societal perspective. Due to
absence of available opportunity costs, tariffs were used
as an approximation. Human capital approach was used
for calculation of indirect costs. Simple sensitivity analy-
sis was performed by varying the tariffs, valuing caregiv-
ing at 40% of the average wage and taking into account
extreme values of direct and indirect costs in each group.
RESULTS: From the societal perspective the mean total
cost /patient/d was estimated at 71,109 and 132 PLN for
stage I, II, and III respectively (1 PLN = €4). Regardless
of EDSS stage indirect costs exceeded direct costs and
were estimated at 46, 73, and 84 PLN/patient/d for stage
I, II, and III respectively. The increase of total, direct
medical and indirect costs associated with progression of
disease was statistically signiﬁcant. The major medical
cost drivers were rehabilitation and hospitalizations. The
percentage of direct costs covered by public payer was
80% for stage I and II and 60% for stage III. Results were
sensitive to the variation applied, but the overall trend
remained as in the primary analysis. CONCLUSION:
This study conﬁrms that MS represents a high economic
burden, with indirect costs greatly exceeding direct costs.
As costs increase with disease progression, treatment
efforts should focus on patients in the early stages of MS.
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RETROSPECTIVE EVALUATION OF THE DOSE
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MANAGEMENT OF CERVICAL DYSTONIA OR
BLEPHAROSPASM—COST CONSIDERATIONS
FOR THE REAL DOSE STUDY
Marchetti A1, Magar R1,Ahmed F2, Findley L3, Larsen JP4,
Pirtosek Z5, Ruzicka E6, Slawek J7
1Thomson Health Economics Research, Secaucus, NJ, USA;
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OBJECTIVE: Assess utilization of Dysport and BOTOX
for cervical dystonia and blepharospasm and compute the
cost consequences of toxin selection. METHODS: Six
European study sites abstracted drug utilization data
from the records of their patients who had received
Dysport then BOTOX or BOTOX then Dysport in a drug
crossover that occurred in clinical practice. To reduce
potential selection bias and confounding variables,
patient records were screened for study inclusion/exclu-
sion criteria during scheduled clinic visits. Patients were
screen-qualiﬁed if they were ≥18 years of age, medically
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stable, responsive to persistent toxin therapy for ≥1 year
before and after drug crossover, did not receive other
medications that affect neuromuscular transmission, 
and were not involved in another drug study. Mean 
per-patient, per-visit and total toxin dose, dosing ratio
(Dysport: BOTOX), and frequencies of adverse drug reac-
tions (ADRs) were computed along with break-even drug
cost equivalence in 5 of 6 participating sites. RESULTS:
One hundred fourteen screen-qualiﬁed patients (70 cervi-
cal dystonia, 44 blepharospasm) were assessed, providing
1,399 injections for evaluation. Ratios of mean dose
(units) Dysport: BOTOX ranged from 2 :1 to 11 :1, with
88% of patients greater than 3 :1, regardless of study site
or direction of drug cross-over. ADRs were more fre-
quently reported during Dysport treatment (11%) than
during BOTOX treatment (4.25%). Drug unit cost equiv-
alence (Dysport to BOTOX) based on local pricing were
2.0 :1 for the Czech Republic, 3.91 :1 in the UK (Hull and
Essex), 4.16 :1 in Slovenia, and 5.24 :1 in Poland. When
observed mean dose ratios were compared to cost equiv-
alent ratios, the proportion of patients that would con-
tribute to cost savings if BOTOX were exclusively utilized
is 63%. CONCLUSION: BOTOX utilization likely leads
to cost savings, based on utilization and current pricing
compared to Dysport. When other important considera-
tions such as ADRs are considered, overall savings may
be even greater.
PNM18
COST-EFFECTIVENESS OF Z DRUGS
(ZOLPIDEM, ZOPICLONE AND ZALEPLON)
VERSUS BENZODIAZEPINES FOR THE 
SHORT—TERM MANAGEMENT OF 
INSOMNIA: A SYSTEMATIC LITERATURE
REVIEW
Boland A, Haycox AR, Dundar Y, Dickson R, Walley T
University of Liverpool, Liverpool, United Kingdom
OBJECTIVES: To carry out a systematic review of the
published literature that compares the cost-effectiveness
of newer hypnotic drugs (zolpidem, zopiclone and zale-
plon) with more established hypnotic drugs (benzodi-
azepines). The aim of this review was to identify
economic evaluations that had been undertaken in the
context of high quality randomised controlled trials in
order to inform UK NHS decision-making. METHODS:
The search included a number of strategies. Search terms
for electronic databases (MEDLINE, EMBASE, HTA,
DARE, NHSEED, OHE-EED, Cochrane Trials Register)
included a combination of index terms (e.g. sleep initia-
tion and maintenance disorders or insomnia) and free text
words (e.g. insomnia or sleeplessness) combined with spe-
ciﬁc drug terms (e.g. zaleplon or sonata, zolpidem or stil-
noct). Clinical terms were combined with economic terms
(e.g. cost or economic). After scanning the abstracts, all
papers that appeared to be of potential value to the study
were obtained. Using explicit, predetermined criteria, two
reviewers independently identiﬁed studies for inclusion in
the cost-effectiveness review process. Disagreements were
resolved through discussion. RESULTS: Although a large
number of papers (n = 925) was identiﬁed by the cost-
effectiveness search strategies, only 33 were assessed for
inclusion in the review, none of which met the inclusion
criteria. No full economic evaluations alongside ran-
domised controlled trials were identiﬁed either between
or across drug groups. Consequently the results of this
literature search did not lead to the identiﬁcation of any
papers for inclusion in the review. CONCLUSIONS: The
burden of disease associated with insomnia is signiﬁcant.
However, there is a paucity of published economic evi-
dence to support NHS decision-making in this area. It 
is imperative that economic evaluations alongside ran-
domised clinical trials be conducted in order to build a
clinical and economic evidence base to inform decision-
making not only in the UK, but also throughout the
world.
PNM19
RESOURCE UTILISATION AND COSTS OF
PATIENTS WITH SPINAL CORD INJURY (SCI)
AFTER INITIAL REHABILITATION
Hieke K1, Hoser H2
1NEOS Health AG, Binningen, Switzerland;
2Berufsgenossenschaftliche Unfallklinik Hamburg, Germany,
Hamburg, Germany
OBJECTIVES: To identify and evaluate resource utiliza-
tion and related costs of SCI patients after initial reha-
bilitation. Both direct (devices, modiﬁcations of home or
workplace) and indirect (lost productivity) costs were
included and evaluated. METHODS: This was a mono-
center, retrospective chart-review study supplemented
with phone interviews to collect information on home
and workplace modiﬁcations. The last 200 consecutive
patients from the Berufsgenossenschaftliche Unfallklinik
Hamburg, Germany fulﬁlling in- and exclusion criteria
(most importantly: age 18–35, SCI at C6 or below). End-
points: Ability to work, actual working patterns, need
and costs of home and workplace modiﬁcations, need,
and costs of professional help for ADLs, costs of mo-
bility devices. A societal perspective was adopted.
RESULTS: Total cost from an societal perspective per
person in this study was €32,517 (19% devices, 10% pro-
fessional help, 22% home modiﬁcations, 49% indirect
costs) in the ﬁrst year and is estimated at €19,186 for the
following years. This does not include cost for workplace
modiﬁcations for which no reliable data could be col-
lected. However, it may be reasonable to assume this cost
to be in the same order of magnitude as the costs for home
modiﬁcations. Average yearly transfer payments (rent and
social welfare) were estimated at €7301 for each patient.
CONCLUSIONS: Indirect costs are the major cost driver
for SCI-patients, in particular after the ﬁrst year when
initial payments for devices and home modiﬁcations are
done. Investments to increase the share of working
persons with SCI (e.g. by improving mobility and acces-
